The results of the first phase 3 clinical trial with mannan-conjugated allergoids have been presented at the annual EAACI (European Academy of Allergy and Clinical Immunology) Congress in Hamburg.

Mannan-conjugated allergoids are a new concept of dendritic cell-targeted immunotherapy developed by INMUNOTEK.  More info here.

During the congress, the latest clinical studies carried out in Germany wih birch pollen were presented:

• Clinical Development of Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergic patients. Mösges et al.
• Mannan conjugated birch pollen allergoids continuously reduce the combined symptom and medication score with increasing treatment duration in birch pollen allergic patients. Hüffmeier et al.
• Subcutaneous immunotherapy with mannan conjugated birch pollen allergoids immunological data from 3 sequential trials. Raskopf et al.
• Subcutaneous immunotherapy with mannan conjugated birch pollen allergoids safety data from 3 sequential trials. Allekotte et al.
• Subcutaneous immunotherapy with mannan conjugated birch pollen allergoids clinical data from 3 sequential trials. Neuhof et al.

Phase 3 results, as well as the follow-up of subjects enrolled in previous studies, demonstrate the safety and efficacy of these glycoconjugates.

In a Satellite Symposium organized by INMUNOTEK different speakers have presented their experimental and clinical results with these glycoconjugates.

+info 

---

---